 |
|
Effect of Magnesium Sulfate Given for Neuroprotection Before Preterm Birth
A Randomized Controlled Trial
Caroline A. Crowther, MD, FRANZCOG;
Janet E. Hiller, PhD;
Lex W. Doyle, MD, FRACP;
Ross R. Haslam, FRACP; for the Australasian Collaborative Trial of Magnesium Sulphate (ACTOMgSO4) Collaborative Group
JAMA. 2003;290:2669-2676.
Context Prenatal magnesium sulfate may reduce the risk of cerebral palsy or death in very preterm infants.
Objective To determine the effectiveness of magnesium sulfate given for neuroprotection to women at risk of preterm birth before 30 weeks' gestation in preventing pediatric mortality and cerebral palsy.
Design, Setting, and Patients Randomized controlled trial at 16 tertiary hospitals in Australia and New Zealand with stratification by center and multiple pregnancy. A total of 1062 women with fetuses younger than 30 weeks' gestation for whom birth was planned or expected within 24 hours were enrolled from February 1996 to September 2000 with follow-up of surviving children at a corrected age of 2 years.
Interventions Women were randomly assigned to receive a loading infusion of 8 mL (4 g [16 mmol] of 0.5 g/mL of magnesium sulfate solution or isotonic sodium chloride solution [0.9%]) for 20 minutes followed by a maintenance infusion of 2 mL/h for up to 24 hours.
Main Outcome Measures Rates of total pediatric mortality, cerebral palsy, and the combined outcome of death or cerebral palsy at a corrected age of 2 years.
Results Data were analyzed for 1047 (99%) 2-year survivors. Total pediatric mortality (13.8% vs 17.1%; relative risk [RR], 0.83; 95% confidence interval [CI], 0.64-1.09), cerebral palsy in survivors (6.8% vs 8.2%; RR, 0.83; 95% CI, 0.54-1.27), and combined death or cerebral palsy (19.8% vs 24.0%; RR, 0.83; 95% CI, 0.66-1.03) were less frequent for infants exposed to magnesium sulfate, but none of the differences were statistically significant. Substantial gross motor dysfunction (3.4% vs 6.6%; RR, 0.51; 95% CI, 0.29-0.91) and combined death or substantial gross motor dysfunction (17.0% vs 22.7%; RR, 0.75; 95% CI, 0.59-0.96) were significantly reduced in the magnesium group.
Conclusions Magnesium sulfate given to women immediately before very preterm birth may improve important pediatric outcomes. No serious harmful effects were seen.
Author Affiliations: Departments of Obstetrics and Gynaecology (Dr Crowther) and Public Health (Dr Hiller), The University of Adelaide, and Department of Neonatal Medicine, Women's and Children's Hospital (Dr Haslam), Adelaide, South Australia; and Departments of Obstetrics and Gynaecology and Paediatrics, The University of Melbourne, The Royal Women's Hospital, Melbourne, Victoria, Australia (Dr Doyle).
RELATED LETTERS
Magnesium Sulfate for Preterm Neuroprotection
Cande V. Ananth and Anthony M. Vintzileos
JAMA. 2004;291(8):940.
EXTRACT
| FULL TEXT
Magnesium Sulfate for Preterm Neuroprotection
Robert Mittendorf, Kwang-Sun Lee, Nancy J. Roizen, and Peter G. Pryde
JAMA. 2004;291(8):940-941.
EXTRACT
| FULL TEXT
Magnesium Sulfate for Preterm Neuroprotection—Reply
Caroline A. Crowther, Janet E. Hiller, Lex W. Doyle, and Ross R. Haslam
JAMA. 2004;291(8):941.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Chorioamnionitis and Cerebral Palsy in Term and Near-Term Infants
Yvonne W. Wu, Gabriel J. Escobar, Judith K. Grether, Lisa A. Croen, John D. Greene, and Thomas B. Newman
JAMA. 2003;290(20):2677-2684.
ABSTRACT
| FULL TEXT
Hope for Perinatal Prevention of Cerebral Palsy
Jon E. Tyson and Larry C. Gilstrap
JAMA. 2003;290(20):2730-2732.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Neuroprotective Strategies for the Neonatal Brain
Degos et al.
Anesth. Analg. 2008;106:1670-1680.
ABSTRACT
| FULL TEXT
Benefit of Magnesium Sulfate Given Before Very Preterm Birth to Protect Infant Brain
Marret et al.
Pediatrics 2008;121:225-226.
FULL TEXT
Prevention of Preterm Delivery
Simhan and Caritis
NEJM 2007;357:477-487.
FULL TEXT
Magnesium Sulfate Compared With Nifedipine for Acute Tocolysis of Preterm Labor: A Randomized Controlled Trial
Lyell et al.
Obstet Gynecol 2007;110:61-67.
ABSTRACT
| FULL TEXT
Magnesium Sulfate Tocolysis: Time to Quit
Mittendorf
Obstet Gynecol 2007;109:1204-1205.
FULL TEXT
Magnesium Sulfate Tocolysis: Time to Quit
Macones et al.
Obstet Gynecol 2007;109:450-451.
FULL TEXT
Magnesium sulfate tocolysis: time to quit.
Grimes and Nanda
Obstet Gynecol 2006;108:986-989.
ABSTRACT
| FULL TEXT
Growth Rate of Corpus Callosum in Very Premature Infants
Anderson et al.
Am. J. Neuroradiol. 2005;26:2685-2690.
ABSTRACT
| FULL TEXT
Morphine, Hypotension, and Adverse Outcomes Among Preterm Neonates: Who's to Blame? Secondary Results From the NEOPAIN Trial
Hall et al.
Pediatrics 2005;115:1351-1359.
ABSTRACT
| FULL TEXT
Can Electronic Fetal Monitoring Identify Preterm Neonates With Cerebral White Matter Injury?
Althaus et al.
Obstet Gynecol 2005;105:458-465.
ABSTRACT
| FULL TEXT
The Role of the Intrauterine and Perinatal Environment in Cerebral Palsy
Paneth et al.
NeoReviews 2005;6:e133-e140.
FULL TEXT
Why is there a modifying effect of gestational age on risk factors for cerebral palsy?
Greenwood et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2005;90:F141-F146.
ABSTRACT
| FULL TEXT
Magnesium Inhibits Norepinephrine Release by Blocking N-Type Calcium Channels at Peripheral Sympathetic Nerve Endings
Shimosawa et al.
Hypertension 2004;44:897-902.
ABSTRACT
| FULL TEXT
Other articles noted: 14 Nov 2003 to 30 Jan 2004
Evid. Based Nurs. 2004;7:e2-e2.
FULL TEXT
Magnesium Sulfate for Preterm Neuroprotection
Ananth and Vintzileos
JAMA 2004;291:940-940.
FULL TEXT
Magnesium Sulfate for Preterm Neuroprotection
Mittendorf et al.
JAMA 2004;291:940-941.
FULL TEXT
Magnesium Sulfate for Neuroprotection? The Evidence Remains Inconclusive
JWatch Women's Health 2004;2004:3-3.
FULL TEXT
Hope for Perinatal Prevention of Cerebral Palsy
Tyson and Gilstrap
JAMA 2003;290:2730-2732.
FULL TEXT
|
